Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06066996 · ClinicalTrials.gov registry record · Early Phase 1
Evaluation of the Electronic Cigarette Withdrawal Syndrome
A Early Phase 1 study of E-cigarette Use and Withdrawal, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT06066996: Recruiting Early Phase 1 study of E-cigarette Use and Withdrawal, sponsored by Johns Hopkins University.
NCT06066996 is a Early Phase 1 study of E-cigarette Use and Withdrawal that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 150 participants, below the 192-participant average among 12 other E-cigarette Use trials with a reported enrollment target (22% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06066996, a Early Phase 1 study of E-cigarette Use and Withdrawal, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this project is to rigorously evaluate the nature of e-cigarette withdrawal in exclusive e-cigarette users during a monitored abstinence period and the role of nicotine in the expression of this withdrawal syndrome.
Primary Outcome
The Hughes-Hatsukami Withdrawal Scale consists of 13 items presented individually on a 100mm visual analog scale. Higher scores reflect higher withdrawal (worse outcome) \[range 0-32\]. Measures are taken at baseline, 8am, 12pm, 4pm, and 8pm every day during the seven day residential stay.
Conditions Studied
Interventions
- DRUG Transdermal Nicotine Patch
- DRUG Placebo Nicotine Patch
Study Locations (1)
Maryland
- Behavioral Pharmacology Research Unit - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2023-11-28 |
| Est. Completion | 2028-06-30 |
| Phase | Early Phase 1 |
What NCT06066996 shows while recruiting
NCT06066996 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 192-participant average among 12 other E-cigarette Use trials with a reported enrollment target (22% lower).
The record links to 2 conditions, with E-cigarette Use appearing as the primary indexed condition, and to 2 interventions - of which Transdermal Nicotine Patch is the first listed.
NCT06066996 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06066996 about?
NCT06066996 is a clinical study titled "Evaluation of the Electronic Cigarette Withdrawal Syndrome". The goal of this project is to rigorously evaluate the nature of e-cigarette withdrawal in exclusive e-cigarette users during a monitored abstinence period and the role of nicotine in the expression of this withdrawal syndrome.
What is the current status of trial NCT06066996?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 150 participants. The study started on 2023-11-28. Estimated completion is 2028-06-30.
What conditions does trial NCT06066996 study?
This clinical trial studies the following conditions: E-cigarette Use, Withdrawal.
What interventions are being tested in trial NCT06066996?
The interventions under investigation include: Transdermal Nicotine Patch (DRUG), Placebo Nicotine Patch (DRUG).
Who is sponsoring clinical trial NCT06066996?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06066996 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for E-cigarette Use
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06066996's enrollment target sits among peer trials
150 5th of 12 higher than 8 of 12 other E-cigarette Use trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other E-cigarette Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sex Differences in the Vascular Effects of E-cigarette Use
RECRUITING · Early Phase 1
-
A Trial of Varenicline for E-cigarette Cessation
RECRUITING · Phase 2
-
Vape-Free Text-Messaging: Pilot Study
RECRUITING · NA
-
Effects of a Low Nicotine Standard and Tobacco Prices on Illegal Cigarette Purchasing
RECRUITING · NA
-
Noncombustible Nicotine Delivery Systems as Potential Harm Reduction Tools for Persistent Cigarette Smokers
RECRUITING · NA
-
An Online Intervention to Reduce E-cigarette Use and Susceptibility to Smoking in Young Adults
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI